http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Rifampicin과 Ofloxacin에 내성인 Bifidobacterium bifidum 균주의 개발
정영자,전명인,강창율,김병각,최응칠,Chung, Young-Ja,Jeon, Myoung-In,Kang, Chang-Youl,Kim, Byoung-Kak,Choi, Eung-Chil 대한약학회 1994 약학회지 Vol.38 No.6
Bifidobacterium bifidum, one strain of medical preparation being on the market for human intestinal disorders, was sensitive to rifampicin and fluoroquinolones. If this preparation is taken with rifampicin and fluoroquinolones, its therapeutic effect can't be expected. Serial passage of B. bifidum RFR61, which was obtained by MNNG mutation method, on agar with 2-fold minimal inhibitory concentration of ofloxacin produced B. bifidum OFR9 with minimal inhibitory contentrations of fluoroquinolones up to $4{\sim}256-fold$ higher than that for the original strain. B. bifidum OFR9 produced almost the same amount of organic acid as parental strain. This strain showed growth inhibitory activity against E. coli NM522, Shigella dysenteriae ATCC9752 and E. coli 078. No inactivations of rifampicin and ofloxacin by this resistant mutant strain were found.
Phellinus linteus 균사 배양물로부터 분리한 단백다당체 Kp의 항암활성
정경수(Kyeong Soo Chung),김신숙(Shin Sook Kim),김희수(Hee Soo Kim),한만우(Man Woo Han),김병각(Byoung Kak Kim) 대한약학회 1994 약학회지 Vol.38 No.2
A protein-polysaccaride fraction Kp(53.9% polysaccharide, 14.2% protein) was separated from the shake-cultured mycelia of a basidiomycetous fungus, Phellinus linteus, and its antitumor activity against sarcoma 180 in ICR mice was investigated. When administered after the tumor implantation, Kp exerted antitumor activity by inhibiting the growth of the sarcoma 180 solid tumor by 71.5% and increasing the life span of the sarcoma 180 ascitic mice by 51.5% at 100 mg/kg. In pretreatment tests, in which Kp was administered once daily for 9 days before the tumor implantation, Kp inhibited the growth of the solid and ascites form of sarcoma 180, respectively, by 35.4% and by 80.3% at 100 mg/kg. However, Kp showed no in vitro cytotoxic activity against a murine leukemia L1210 and a human gastric tumor SNU.1 upto the concentration of 200 mcg/ml. From these results, it is clear that the antitumor activity of Kp is exerted through its immunomodulating activity on the host''s immune system.
마크로라이드-린코사마이드-스트렙토그라민 B(MLS)계 항생물질에 대한 유도 내성
권애란(Ae Ran Kwon),최성숙(Sung Sook Choi),김숙경(Sook Kyung Kim),정영자(Young Ja Chung),최응칠(Eung Chil Choi),김병각(Byoung Kak Kim) 대한약학회 1994 약학회지 Vol.38 No.3
Forty nine clinical isolates of S. aureus showing resistance to erythromycin(EM) were selected from 83 strains isolated recently in Korea. Fourteen strains of S. aureus showing inducible resistance to MLS antibiotics were selected by disc agar diffusion method. Colony hydridization was executed using two MLS inducible resistance genes, ermA and ermC, identified previously from S. aureus as probes. S. aureus 375 and S. aureus 507 whose genes were not homologous to those probes were finally selected. It was confirmed that the resistance genes of S. aureus 375 and S. aureus 507 had no homology with those probes in southern hybridization test using ermA, ermC and ermAM as probes. It was determined that S. aureus 375 had a plasmid whose size was about 35 kb. To know if the plasmid may have the genes related to inducible resistance to MLS antibiotics, it was attempted to transform Bacillus subtillis BR151 and S. aureus RN4220 with the plasmid isolated from S. aureus 375. It was shown that the gene related to inducible resistance to MLS antibiotics did not exist in this plasmid. These results indicate that two clinical isolates of S. aureus showing inducible resistance to MLS antibiotics have novel genes that have no homology with MLS resistance genes identified so far. It is assumed that these genes may exist in chromosomal DNA.
리팜피신에 내성인 Bifidobacterium bifidum 균주개발
최응칠(Eung Chil Choi),고성열(Sung Youl Ko),김희선(Hee Sun Kim),최성숙(Sung Sook Choi),김숙경(Sook Kyung Kim),김병각(Byoung Kak Kim) 대한약학회 1993 약학회지 Vol.37 No.5
Bifidobacterium bifidum, one strain of medical preparations being on the market for human intestinal disorder, is very sensitive to rifampicin. If this preparation is taken with rifampicin, its therapeutic effect can't be expected. To develope rifampicin resistant mutants, B. bifidum was treated with N-methyl-N''-nitro-N-nitrosoguanidine(MNNG). All of thirty strains grown on the plates containing 10 mcg/ml rifampicin were over 1,000 times more resistant to rifampicin than parental strain and they were identified as B. bifidum by fructose-6-phosphoate phosphoketolase test. Three strains out of thirty, which produced almost same amount of organic acid as parental strain, were selected for further studies. They showed identical growth inhibition activity aganist E. coli compared with that of parental strain. And rifampicin was not inactivated.